Development of a Promising Bivalent Vaccine Against Klebsiella pneumoniae Based on Glycoengineered GMMA (geGMMA)

Abstract

Multidrug-resistant Klebsiella pneumoniae constitutes a significant threat as a nosocomial pathogen, and no licensed vaccines are currently available. Generalized modules for membrane antigens (GMMA) have recently been recognized as a promising platform for developing outer membrane vesicle (OMV) vaccines against numerous infectious diseases. The study was carried out in use of the W3110 ΔwbbH-L ΔlpxM::lpxE in which E. coli was treated in order to eliminate the endogenous polysaccharide and use two new ones (polysaccharides from Klebsiella). The exogenous polysaccharides were accurately displayed on the surface of spontaneously released OMVs. The immune responses evoked by subcutaneous administration of these vaccines were evaluated, and the protective effects were assessed using a mouse intraperitoneal challenge model. Interference in the biosynthesis of endogenous polysaccharides (such as deleting related gene clusters) is a viable approach to increasing the yield of glycoengineered GMMA vaccines (geGMMA). The geGMMA platform, which is conducive to safer large-scale production, lays the foundations for the development of GMMA vaccines decorated with exogenous glycan antigens derived from pathogenic bacteria.

Keywords

Klebsiella pneumoniae / geGMMA / vaccine / platform

References

[1] L. K. Siu, K. M. Yeh, J. C. Lin, C. P. Fung, and F. Y. Chang, “Klebsiella pneumoniae Liver Abscess: A New Invasive Syndrome,” The Lancet Infectious Diseases12 (2012): 881-887.

[2] K. Z. Vardakas, G. S. Tansarli, P. I. Rafailidis, and M. E. Falagas, “Carbapenems Versus Alternative Antibiotics for the Treatment of Bacteraemia Due to Enterobacteriaceae Producing Extended-Spectrum-Lactamases: A Systematic Review and Meta-Analysis,” Journal of Antimicrobial Chemotherapy67 (2012): 2793-2803.

[3] N. Padmini, A. A. K. Ajilda, N. Sivakumar, and G. Selvakumar, “Extended Spectrum β-Lactamase Producing Escherichia coli and Klebsiella pneumoniae: Critical Tools for Antibiotic Resistance Pattern,” Journal of Basic Microbiology57 (2017): 460-470.

[4] P. L. Wantuch and D. A. Rosen, “Klebsiella pneumoniae: Adaptive Immune Landscapes and Vaccine Horizons,” Trends in Immunology44 (2023): 826-844.

[5] K. Hu, E. Palmieri, K. Samnuan, et al., “Generalized Modules for Membrane Antigens (GMMA), an Outer Membrane Vesicle-Based Vaccine Platform, for Efficient Viral Antigen Delivery,” Journal of Extracellular Vesicles11 (2022): e12247.

[6] F. Mancini, O. Rossi, F. Necchi, and F. Micoli, “OMV Vaccines and the Role of TLR Agonists in Immune Response,” International Journal of Molecular Sciences21 (2020): 4416.

[7] F. Micoli, R. Adamo, and U. Nakakana, “Outer Membrane Vesicle Vaccine Platforms,” Biodrugs38 (2023): 47-59.

[8] M. G. Sartorio, E. J. Pardue, M. F. Feldman, and M. F. Haurat, “Bacterial Outer Membrane Vesicles: From Discovery to Applications,” Annual Review of Microbiology75 (2021): 609-630.

[9] P. T. Beernink, E. Ispasanie, L. A. Lewis, S. Ram, G. R. Moe, and D. M. Granoff, “A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies,” Journal of Infectious Diseases219 (2019): 1130-1137.

[10] K. Cheng, R. Zhao, Y. Li, et al., “Bioengineered Bacteria-Derived Outer Membrane Vesicles as a Versatile Antigen Display Platform for Tumor Vaccination via Plug-and-Display Technology,” Nature Communications12 (2021): 2041.

[11] Y. Han, Y. Li, J. Chen, Y. Tan, F. Guan, and X. Wang, “Construction of Monophosphoryl Lipid A Producing Escherichia coli Mutants and Comparison of Immuno-Stimulatory Activities of Their Lipopolysaccharides,” Marine Drugs11 (2013): 363-376.

[12] Y. Li, Z. Wang, J. Chen, R. K. Ernst, and X. Wang, “Influence of Lipid A Acylation Pattern on Membrane Permeability and Innate Immune Stimulation,” Marine Drugs11 (2013): 3197-3208.

[13] D. J. Dowling, H. Sanders, W. K. Cheng, et al., “A Meningococcal Outer Membrane Vesicle Vaccine Incorporating Genetically Attenuated Endotoxin Dissociates Inflammation From Immunogenicity,” Frontiers in Immunology7 (2016): 562.

[14] P. B. Keiser, S. Biggs-Cicatelli, E. E. Moran, et al., “A Phase 1 Study of a Meningococcal Native Outer Membrane Vesicle Vaccine Made From a Group B Strain With Deleted lpxL1 and synX, Over-Expressed Factor H Binding Protein, Two PorAs and Stabilized OpcA Expression,” Vaccine29 (2011): 1413-1420.

[15] O. Rossi, M. Caboni, A. Negrea, et al., “Toll-Like Receptor Activation by Generalized Modules for Membrane Antigens From Lipid A Mutants of Salmonella Enterica Serovars Typhimurium and Enteritidis,” Clinical and Vaccine Immunology: CVI23 (2016): 304-314.

[16] O. Rossi, I. Pesce, C. Giannelli, et al., “Modulation of Endotoxicity of Shigella Generalized Modules for Membrane Antigens (GMMA) by Genetic Lipid A Modifications,” Journal of Biological Chemistry289 (2014): 24922-24935.

[17] F. Mancini, F. Micoli, F. Necchi, M. Pizza, F. Berlanda Scorza, and O. Rossi, “GMMA-Based Vaccines: The Known and The Unknown,” Frontiers in Immunology12 (2021): 715393.

[18] C. Gerke, A. M. Colucci, C. Giannelli, et al., “Production of a Shigella Sonnei Vaccine Based on Generalized Modules for Membrane Antigens (GMMA), 1790GAHB,” PLoS One10 (2015): e0134478.

[19] F. Berlanda Scorza, A. M. Colucci, L. Maggiore, et al., “High Yield Production Process for Shigella Outer Membrane Particles,” PLoS One7 (2012): e35616.

[20] O. Koeberling, E. Ispasanie, J. Hauser, et al., “A Broadly-Protective Vaccine Against Meningococcal Disease in sub-Saharan Africa Based on Generalized Modules for Membrane Antigens (GMMA),” Vaccine32 (2014): 2688-2695.

[21] H. Chi, X. Wang, Y. Shao, et al., “Engineering and Modification of Microbial Chassis for Systems and Synthetic Biology,” Synthetic and Systems Biotechnology4 (2018): 25-33.

[22] M. E. Pennini, A. De Marco, M. Pelletier, et al., “Immune Stealth-Driven O2 Serotype Prevalence and Potential for Therapeutic Antibodies Against Multidrug Resistant Klebsiella Pneumoniae,” Nature Communications8 (2017): 1991.

[23] Z. Peng, J. Wu, K. Wang, et al., “Production of a Promising Biosynthetic Self-Assembled Nanoconjugate Vaccine Against Klebsiella Pneumoniae Serotype O2 in a General Escherichia Coli Host,” Advanced Science8 (2021): e2100549.

[24] J. Brown, A. J. Clippinger, C. Fritz Briglia, et al., “Using the Monocyte Activation Test as a Stand-Alone Release Test for Medical Devices,” Altex38 (2021): 151-156.

[25] Y. Liu, C. Pan, K. Wang, et al., “Preparation of a Klebsiella pneumoniae Conjugate Nanovaccine Using Glycol-Engineered Escherichia coli,” Microbial Cell Factories22 (2023): 95.

[26] T. A. Ahmad, L. H. El-Sayed, M. Haroun, A. A. Hussein, and E. S. H. El Ashry, “Development of Immunization Trials Against Klebsiella pneumoniae,” Vaccine30 (2012): 2411-2420.

[27] W. Li, Y. Hu, Q. Zhang, et al., “Development of Drug-Resistant Klebsiella pneumoniae Vaccine via Novel Vesicle Production Technology,” ACS Applied Materials & Interfaces13 (2021): 32703-32715.

[28] W. H. Lee, H. I. Choi, S. W. Hong, K. S. Kim, Y. S. Gho, and S. G. Jeon, “Vaccination With Klebsiella pneumoniae-Derived Extracellular Vesicles Protects Against Bacteria-Induced Lethality via Both Humoral and Cellular Immunity,” Experimental & Molecular Medicine47 (2015): e183.

[29] G. Wu, H. Ji, X. Guo, et al., “Nanoparticle Reinforced Bacterial Outer-Membrane Vesicles Effectively Prevent Fatal Infection of Carbapenem-Resistant Klebsiella pneumoniae,” Nanomedicine24 (2020): 102148.

[30] K. S. Park, K. Svennerholm, R. Crescitelli, et al., “Detoxified Synthetic Bacterial Membrane Vesicles as a Vaccine Platform Against Bacteria and SARS-CoV-2,” Journal Nanobiotechnology21 (2023): 156.

[31] S. Schild, E. J. Nelson, A. L. Bishop, and A. Camilli, “Characterization of Vibrio Cholerae Outer Membrane Vesicles as a Candidate Vaccine for Cholera,” Infection and Immunity77 (2009): 472-484.

[32] M. Muralinath, M. J. Kuehn, K. L. Roland, and R. Curtiss, “Immunization With Salmonella Enterica Serovar Typhimurium-Derived Outer Membrane Vesicles Delivering the Pneumococcal Protein PspA Confers Protection Against Challenge With Streptococcus pneumoniae,” Infection and Immunity79 (2011): 887-894.

[33] S. H. Kim, K. S. Kim, S. R. Lee, et al., “Structural Modifications of Outer Membrane Vesicles to Refine Them as Vaccine Delivery Vehicles,” Biochimica Et Biophysica Acta1788 (2009): 2150-2159.

[34] N. C. Kesty and M. J. Kuehn, “Incorporation of Heterologous Outer Membrane and Periplasmic Proteins Into Escherichia coli Outer Membrane Vesicles,” Journal of Biological Chemistry279 (2004): 2069-2076.

[35] L. Fantappiè, M. de Santis, E. Chiarot, et al., “Antibody-Mediated Immunity Induced by Engineered Escherichia coli OMVs Carrying Heterologous Antigens in Their Lumen,” Journal of Extracellular Vesicles3 (2014): 24015.

[36] E. Bartolini, E. Ianni, E. Frigimelica, et al., “Recombinant Outer Membrane Vesicles Carrying Chlamydia Muridarum HtrA Induce Antibodies That Neutralize Chlamydial Infection in Vitro,” Journal of Extracellular Vesicles2 (2013): 20181.

[37] F. Micoli, R. Alfini, R. Di Benedetto, et al., “Generalized Modules for Membrane Antigens as Carrier for Polysaccharides: Impact of Sugar Length, Density, and Attachment Site on the Immune Response Elicited in Animal Models,” Frontiers in Immunology12 (2021): 719315.

[38] F. Micoli, R. Alfini, R. Di Benedetto, et al., “GMMA is a Versatile Platform to Design Effective Multivalent Combination Vaccines,” Vaccines8 (2020): 540.

[39] P. V. Scaria, C. G. Rowe, B. B. Chen, et al., “Outer Membrane Protein Complex as a Carrier for Malaria Transmission Blocking Antigen Pfs230,” nPJ Vaccines4 (2019): 24.

[40] Y. Wu, C. Przysiecki, E. Flanagan, et al., “Sustained High-titer Antibody Responses Induced by Conjugating a Malarial Vaccine Candidate to Outer-membrane Protein Complex,” Proceedings National Academy of Science USA103 (2006): 18243-18248.

[41] M. Wang, Y. Tian, L. Xu, et al., “High Osmotic Stress Increases OmpK36 Expression Through the Regulation of KbvR to Decrease the Antimicrobial Resistance of Klebsiella pneumoniae,” Microbiology Spectrum10 (2022): e0050722.

[42] Y. K. Tsai, C. P. Fung, J. C. Lin, et al., “Klebsiella pneumoniae Outer Membrane Porins OmpK35 and OmpK36 Play Roles in both Antimicrobial Resistance and Virulence,” Antimicrobial Agents and Chemotherapy55 (2011): 1485-1493.

[43] P. Jeannin, B. Bottazzi, M. Sironi, et al., “Complexity and Complementarity of Outer Membrane Protein A Recognition by Cellular and Humoral Innate Immunity Receptors,” Immunity22 (2005): 551-560.

[44] P. Jeannin, G. Magistrelli, L. Goetsch, et al., “Outer Membrane Protein A (OmpA): A New Pathogen-Associated Molecular Pattern That Interacts With Antigen Presenting Cells—Impact on Vaccine Strategies,” Vaccine20, no. S4 (2002): A23-A27.

[45] P. A. van der Ley, A. Zariri, E. van Riet, D. Oosterhoff, and C. P. Kruiswijk, “An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity against a SARS-CoV-2 Infection,” Frontiers in Immunology12 (2021): 781280.

[46] Y. Kohara, K. Akiyama, and K. Isono, “The Physical Map of the Whole E. coli Chromosome: Application of a New Strategy for Rapid Analysis and Sorting of a Large Genomic Library,” Cell50 (1987): 495-508.

[47] K. Tan, R. Li, X. Huang, and Q. Liu, “Outer Membrane Vesicles: Current Status and Future Direction of these Novel Vaccine Adjuvants,” Frontiers in Microbiology9 (2018): 00783.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.